Nature Communications (Jul 2019)
An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis
- Harvey W. Smith,
- Alison Hirukawa,
- Virginie Sanguin-Gendreau,
- Ipshita Nandi,
- Catherine R. Dufour,
- Dongmei Zuo,
- Kristofferson Tandoc,
- Matthew Leibovitch,
- Salendra Singh,
- Jonathan P. Rennhack,
- Matthew Swiatnicki,
- Cynthia Lavoie,
- Vasilios Papavasiliou,
- Carolin Temps,
- Neil O. Carragher,
- Asier Unciti-Broceta,
- Paul Savage,
- Mark Basik,
- Vincent van Hoef,
- Ola Larsson,
- Caroline L. Cooper,
- Ana Cristina Vargas Calderon,
- Jane Beith,
- Ewan Millar,
- Christina Selinger,
- Vincent Giguère,
- Morag Park,
- Lyndsay N. Harris,
- Vinay Varadan,
- Eran R. Andrechek,
- Sandra A. O’Toole,
- Ivan Topisirovic,
- William J. Muller
Affiliations
- Harvey W. Smith
- Rosalind and Morris Goodman Cancer Research Centre, McGill University
- Alison Hirukawa
- Rosalind and Morris Goodman Cancer Research Centre, McGill University
- Virginie Sanguin-Gendreau
- Rosalind and Morris Goodman Cancer Research Centre, McGill University
- Ipshita Nandi
- Rosalind and Morris Goodman Cancer Research Centre, McGill University
- Catherine R. Dufour
- Rosalind and Morris Goodman Cancer Research Centre, McGill University
- Dongmei Zuo
- Rosalind and Morris Goodman Cancer Research Centre, McGill University
- Kristofferson Tandoc
- Lady Davis Institute for Medical Research, McGill University
- Matthew Leibovitch
- Lady Davis Institute for Medical Research, McGill University
- Salendra Singh
- Case Comprehensive Cancer Center, Case Western University
- Jonathan P. Rennhack
- Department of Physiology, Michigan State University
- Matthew Swiatnicki
- Department of Physiology, Michigan State University
- Cynthia Lavoie
- Rosalind and Morris Goodman Cancer Research Centre, McGill University
- Vasilios Papavasiliou
- Rosalind and Morris Goodman Cancer Research Centre, McGill University
- Carolin Temps
- Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh
- Neil O. Carragher
- Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh
- Asier Unciti-Broceta
- Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh
- Paul Savage
- Rosalind and Morris Goodman Cancer Research Centre, McGill University
- Mark Basik
- Case Comprehensive Cancer Center, Case Western University
- Vincent van Hoef
- Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institute
- Ola Larsson
- Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institute
- Caroline L. Cooper
- Department of Anatomical Pathology, Pathology Queensland, Princess Alexandra Hospital
- Ana Cristina Vargas Calderon
- Douglass Hanly Moir Pathology
- Jane Beith
- Chris O’Brien Lifehouse
- Ewan Millar
- Department of Anatomical Pathology, South Eastern Area Laboratory Service, St George Public Hospital
- Christina Selinger
- Dept of Tissue Pathology and Diagnostic Oncology, Royal Prince Albert Hospital
- Vincent Giguère
- Rosalind and Morris Goodman Cancer Research Centre, McGill University
- Morag Park
- Rosalind and Morris Goodman Cancer Research Centre, McGill University
- Lyndsay N. Harris
- Case Comprehensive Cancer Center, Case Western University
- Vinay Varadan
- Case Comprehensive Cancer Center, Case Western University
- Eran R. Andrechek
- Department of Physiology, Michigan State University
- Sandra A. O’Toole
- Sydney Medical School, University of Sydney
- Ivan Topisirovic
- Lady Davis Institute for Medical Research, McGill University
- William J. Muller
- Rosalind and Morris Goodman Cancer Research Centre, McGill University
- DOI
- https://doi.org/10.1038/s41467-019-10681-4
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 19
Abstract
Polycomb Repressor Complex 2 (PRC2) is frequently up-regulated in cancers. Here, the authors show that the tyrosine kinase c-Src stimulates mitochondrial function to signal energy sufficiency to mTORC1, increasing translation of the PRC2 subunits EZH2 and SUZ12 to support ErbB2-dependent tumours.
